Chromosomal Microarray, Hematologic Malignancy, ClariSure Oligo‑SNP
Also known as: ClariSure® Oligo-SNP, Microarray, ClariSure® Oligo-SNP, Lymphoma, Leukemia
Use
This assay is intended to integrate microarray analysis into the investigation of hematologic malignancies, assessing genomic alterations and overall genomic complexity of the abnormal clone. It is used in conjunction with other established laboratory tests for the malignancy in question, providing complementary genomic data including chromosomal deletions, amplifications, and copy‑number neutral SNP changes at MDS‑associated loci. It may increase diagnostic yield in cases where karyotype or morphologic evaluation is nondiagnostic.
Special Instructions
Insurance authorization is required prior to draw for outpatients; inpatients may be sent without prior authorization. Specimen source should be indicated in flag comments, on specimen and batch sheet. Alongside solid tumor biopsy specimens, the corresponding pathology report with diagnosis/clinical indication should be submitted.
Limitations
As a microarray‑based assay, this test cannot detect balanced translocations or low‑level mosaicism below its detection threshold. It complements but does not replace karyotype or FISH and must be interpreted in the context of other laboratory findings.
Methodology
Microarray
Biomarkers
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
1‑3 mL
Minimum Volume
1 mL
Container
Sodium heparin (green‑top) tube
Collection Instructions
Bone marrow collected in heparin, EDTA (lavender‑top), or ACD A/B (yellow‑top) is acceptable.